Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21962703 | 1.00 | NLRP3 (0.44) | NLRP3TGFBR1APLNRLMNA | |
| SCHEMBL21962705 | 1.00 | NLRP3 (0.44) | NLRP3TGFBR1APLNRLMNA | |
| SCHEMBL22020747 | 0.86 | NLRP3 (0.36) | NLRP3 | |
| SCHEMBL22281789 | 0.83 | NLRP3 (0.52) | NLRP3 | |
| SCHEMBL22281794 | 0.83 | NLRP3 (0.52) | NLRP3 | |
| SCHEMBL22281793 | 0.83 | NLRP3 (0.52) | NLRP3 | |
| SCHEMBL22265266 | 0.80 | NLRP3 (0.44) | NLRP3 | |
| SCHEMBL24978386 | 0.80 | NLRP3 (0.44) | NLRP3 | |
| SCHEMBL21962171 | 0.79 | NLRP3 (0.39) | NLRP3TGFBR1LMNA | |
| SCHEMBL21962175 | 0.79 | NLRP3 (0.39) | NLRP3TGFBR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NLRP3 2/4885TGFBR1 4191/4885APLNR 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.